A blog exploring pharmaceutical relationship marketing, emarketing and innovation with a focus on rare disorders.
The convergence of rare disease, digital communications, and pharmaceutical marketing communications

innovation Archive

New Medical Technique Spells Cure for Insidious Rare Disease

Posted by | 3:41pm on Thursday, October 29, 2015 | No Comments
Sickle Cell Anemia peripheral blood smear

In 1973, people with sickle cell disease (SCD) had an average lifespan of only 14 years. But the situation has improved dramatically for patients living with this rare, inherited blood disorder that is primarily prevalent amongst people of African descent. Currently, life expectancy for these patients can reach 50 years and over. Women with the disease tend to live longer than their male peers but ongoing research is giving all affected patients even more reason to hope.

Affected Populations

Sickle cell disease primarily affects people of African descent, including 0.6 percent of the African American population in the U.S. (approximately 90,000 cases). It affects approximately one in every 350 African American newborns.  Americans whose ancestry is Asiatic Indian, Italian, Greek or Mediterranean may also be affected by SCD  Scientists now believe that the mutated gene that causes sickle cell disease occurred in hard-hit malaria populations because the sickle cell trait has been shown to confer some resistance to the mosquito-borne disease.

Treatment Options

Treatments have been woefully inadequate and lead to a diminished quality of life for many sickle cell sufferers.  Patients’ symptoms are managed mainly with narcotic pain medication and blood transfusions.  There are several pharmaceutical companies developing therapies to lessen the frequency and severity of patients’ crises but a cure was out of reach for many individuals—until now.

NIH Study Spurs Hematologist to Undertake His Own

Just two and a half years ago, I penned a blog post about a promising new study taking shape at University of Illinois Hospital & Health Sciences System (UI Health)  in Chicago. Dr. Damiano Rondelli, a hematologist, leveraged findings from a NIH study that reported it was possible to do stem cell transplants in sickle cell disease patients without using chemotherapy and still receive good results.  That was good enough for Dr. Rondelli and he opened a trial mostly based on the large patient population in his clinic.

Out with the Old, in with the New

Doctors have known for some time that bone marrow transplants from a healthy donor can cure sickle cell disease but few adults were candidates for the procedure.  Why?  Prior to release of the NIH study findings, the prerequisite for stem cell transplantation was a course of chemotherapy to kill off the patient’s own cells and prepare the body to accept the new ones.  The chemotherapy could leave patients with weakened immune systems and make them susceptible to infection. This was a very risky proposition for some patients, especially adults, who lived with the debilitating effects of the disease for years and already experienced organ damage as a result.  The procedure was just too risky to undertake in many cases.

Patients receive a very low dose of total body irradiation and immunosuppressive drugs just before the transplant with the new technique. This is a much milder course of treatment, instead of chemotherapy, that results in fewer potentially serious side effects than ever before.

Cure for Adult Sickle Cell Patients Validated by UI Health

Dr. Rondelli and his team performed the first non-chemotherapy transplants outside of the NIH facility in Maryland, where the procedure was developed.  Their trial results have been stunning and according to the press release they have “cured twelve adult patients of sickle cell disease using a unique (non-chemotherapy) procedure for stem cell transplantation from healthy, tissue-matched siblings.”  The results of the phase I/II clinical trial at UI Health, in which 92 percent of treated patients were cured, are published online in the Biology of Blood & Marrow Transplantation journal. It should be noted that UI Health’s 92 percent cure rate eclipses the 87 percent success rate of the NIH study.

UI Health Furthers Advancement 

It is one thing to leverage a study’s findings and replicate the results but another when you are able to improve upon the results and advance the findings.  This is just what happened at UI Health.  In addition to achieving a five percent higher success rate, UI Health successfully transplanted two patients with cells from siblings who matched for human leukocyte antigen (HLA) but had a different blood type.

According to the UI Health press release, one year after transplantation the 12 successfully transplanted patients had normal hemoglobin concentrations in their blood and better cardiopulmonary function.   Four of the patients were able to stop post-transplantation immunotherapy without transplant rejection or other complications.

The Future is Brighter

An inspired hematologist from Chicago and his team pounced on a NIH study and brought its findings to their clinic for further investigation and trial. Several years later their validation that adults with SCD can undergo stem cell transplantation without harmful chemotherapy and be cured of this debilitating condition is very exciting news indeed and holds promise for a much brighter future for thousands of SCD patients and their families. 


Image courtesy of Ed Uthman on Flickr (CC BY).

FacialMetricsPresenting the additiontoRecognyz to the judges_L2RAfrahShafquat-JeremyWilliams-MichaelRogove

How Technology Will Improve the Future for Rare Diseases

Our collaboration with Global Genes and Sharon Moalem, MD, PhD at H@cking Medicine at the Massachusetts Institute of Technology (MIT)…

Tags: , , ,


On the Frontlines of Healthcare Innovation

Earlier this month, I had the opportunity to participate in an event aiming to innovate and disrupt some of healthcare’s…

Tags: , , , ,

5 Ways to Speed Diagnosis of Our Children

You have probably heard the statistics before. There are 7,000 rare diseases. More than 80% are genetic. Half of those…

Tags: , , , , ,

US Supreme Court Building

Supreme Court Ruling Impacts Genetic Research

On June 13, 2013, the US Supreme Court ruled that human genes may not be patented. The unanimous decision will…


The Latest in Gene Therapy Research

Gene therapy was the topic at the Healthcare Businesswomen’s Association event on April 30 with Ricki Lewis, PhD. The crowd…


doctor's hands holding stethoscope

What Is Personalized Medicine?

“’Personalized medicine’ refers to the tailoring of medical treatment to the individual characteristics of each patient,” according to the President’s…


Leading With Passion

I was recently among several Chicago CEOs asked to discuss leadership by CEO IntroNet. The invitation resulted from Siren’s selection…


InnovationPharm: What’s New in Search & YouTube

To keep up with what’s new and innovative in technology, as well as the biopharmaceutical industry, we have a learning…


Digital Marketing or Marketing in a Digital World?

“We don’t believe in digital marketing. We believe in marketing in a digital world, and there’s a huge difference,” said…


pills and tablets scattered on table

Innovation at the Margins: Rare Disease Research

Rare disease research is on the rise, and that’s good news for the 25 million rare disorder patients in the…


What’s Foursquare & Why Should I Care?

I’m not embarrassed to admit it: I love Foursquare. It may be a silly game, but it shows how technology…


Guggenheim Bilboa

Is Innovation a Dirty Word in Pharma Marketing?

Innovation. What a loaded word. And a bit intimidating. But according to Merriam-Webster Dictionary all it means is “the introduction…


Siren Interactive
  • Siren Interactive
  • Rare Disease Relationship Marketing Experts
  • 626 West Jackson Blvd, Suite 100
  • Chicago, IL 60661
  • 312.204.6700
  • 866.502.6714 (Toll Free)
  • www.sireninteractive.com